Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493879 | 0.79 | PTPN1 (0.55) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL22493885 | 0.77 | NPC1 (0.50) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL20873106 | 0.75 | TRPV1 (0.67) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2562031 | 0.75 | TRPV1 (0.75) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4517770 | 0.75 | TRPV1 (0.75) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2914329 | 0.74 | TRPV1 (0.74) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL23657648 | 0.74 | TRPV1 (0.78) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5539768 | 0.74 | TRPV1 (0.78) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| Iodide SCHEMBL30758578 | 0.74 | TRPV1 (0.73) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL23234173 | 0.74 | RAB9A (0.48) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464289-B1 | ULTRA-POTENT VINCA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBULIN DIMER-DIMER INTERFACE | SCRIPPS RESEARCH INST (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | NATIONAL INSTITUTES OF HEALTH | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | TUBA1C, TUBB2A, TUBA1A | TRPV1 3936/4885NPC1 3312/4885RAB9A 1457/4885 |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | TUBA1A, TUBA1C, TUBB2A | TRPV1 3751/4885NPC1 3345/4885RAB9A 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.